$14 million grant awarded to mitigate the impact of cancer on Pacific Islanders

NewsGuard 100/100 Score

The University of Guam and the University of Hawai'i Cancer Center were each awarded five-year grants totaling more than $14 million to mitigate the impact of cancer on Pacific Islanders through cancer research, career training, and community outreach. The collaboration between the two universities, known as the Pacific Island Partnership for Cancer Health Equity (PIPCHE), will be funded by the National Cancer Institute through Aug. 31, 2025.

Funds from the PIPCHE are used to support the research infrastructure needed to address significant cancer health disparities in the Pacific.

PIPCHE has been truly transformational for research here at UOG for this region. Before PIPCHE, there was very little cancer and health-related research occurring of relevance to Guam's population. Now we have multiple federal research grants studying cancer, child obesity, cardiometabolic health, and dementia."

Rachael Leon Guerrero, Ph.D., RD, co-principal investigator of the grant and vice provost of research and sponsored programs at the University of Guam

PIPCHE is the only NCI-funded, Pacific-based partnership that addresses cancer disparities in the peoples of Hawai'i, Guam, and other U.S.-affiliated Pacific Islands, which include the Northern Mariana Islands, American Sāmoa, the Federated States of Micronesia, the Marshall Islands, and Palau. It also provides research training for students and early career scientists while engaging communities in outreach activities to advance knowledge, awareness, behavior change and public health policy in Guam and Hawai'i.

"We use cancer research as a platform to bring equity and resiliency to the indigenous Pacific peoples," said Neal A. Palafox, M.D., MPH, a UH Cancer Center researcher and the principal investigator of the grant at UHCC. "... The investment has brought forward indigenous Pacific cancer researchers and scientific leaders, relevant Pacific-based interventions to address cancer disparities, and has increased the capacity for both institutions to understand and achieve cancer health equity in the Pacific."

The first PIPCHE grant was awarded to the University of Guam and the UH Cancer Center in 2003. Since then, the funds have supported 25 research projects, trained more than 100 underrepresented students and early career scientists, contributed more than 100 peer-reviewed publications, and, in the last cycle alone, acquired more than $34 million in additional external funds to explore research questions that are unique to the Pacific region.

"The 17 years have been a fun and eye-opening voyage," Palafox said.

Cancer prevention and control in the Pacific are shared missions between the UH Cancer Center, the University of Guam, and their collaborators. The PIPCHE provides a platform to do much more than either institution can accomplish alone.

The efforts of this partnership are directed by Leon Guerrero and Palafox as well as UOG School of Health Dean Margaret Hattori-Uchima, Ph.D., RN, and UH Cancer Center Director Randall Holcombe, M.D., MBA, together with a team of more than 50 investigators and staff at the partnering institutions.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer